am 251 and oxidopamine
am 251 has been researched along with oxidopamine in 4 studies
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Caraballo, I; El Banoua, F; Fernandez-Espejo, E; Ferrer, B; Flores, JA; Galan-Rodriguez, B; Rodriguez de Fonseca, F | 1 |
| Kreitzer, AC; Malenka, RC | 1 |
| Belforte, JE; Braz, BY; Galiñanes, GL; Murer, MG | 1 |
| Bortolanza, M; Crivelaro do Nascimento, G; Del Bel, EA; Ferrari, DP; Ferreira-Junior, NC; Guimaraes, FS | 1 |
Other Studies
4 other study(ies) available for am 251 and oxidopamine
| Article | Year |
|---|---|
Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function.
Topics: Acyltransferases; Amidohydrolases; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Arachidonic Acids; Behavior, Animal; Brain Chemistry; Cell Count; Central Nervous System Stimulants; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Endocannabinoids; Functional Laterality; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Wistar; Rotation; Serotonin Antagonists; Serotonin Receptor Agonists; Substantia Nigra; Tyrosine 3-Monooxygenase | 2004 |
Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models.
Topics: Animals; Benzamides; Benzoxazines; Cannabinoid Receptor Modulators; Carbamates; Disease Models, Animal; Dopamine; Dopamine D2 Receptor Antagonists; Endocannabinoids; Excitatory Postsynaptic Potentials; In Vitro Techniques; Long-Term Synaptic Depression; Mice; Mice, Transgenic; Morpholines; Naphthalenes; Neostriatum; Neuronal Plasticity; Oxidopamine; Parkinson Disease; Piperidines; Psychomotor Performance; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Reserpine; Synapses | 2007 |
Properties of the corticostriatal long term depression induced by medial prefrontal cortex high frequency stimulation in vivo.
Topics: Adrenergic Agents; Animals; Animals, Newborn; Benzazepines; Choline O-Acetyltransferase; Corpus Striatum; Dizocilpine Maleate; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Heparin-binding EGF-like Growth Factor; Long-Term Synaptic Depression; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neural Pathways; Neurons; Oxidopamine; Piperidines; Prefrontal Cortex; Pyrazoles; Receptor, Cannabinoid, CB1; Tyrosine 3-Monooxygenase | 2017 |
Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease.
Topics: Amidohydrolases; Analgesics; Animals; Benzamides; Brain; Cannabidiol; Capsaicin; Carbamates; Celecoxib; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Morphine; Nociception; Oxidopamine; Pain; Parkinson Disease; Piperidines; Pyrazoles; Thienamycins | 2020 |